American health insurer Aetna has agreed to pay approximately ₹975 crore ($117.7 million) to settle federal allegations of Medicare billing fraud. The U.S. government accused the company of submitting inaccurate diagnosis codes to secure inflated payments under the Medicare Advantage program. Notably, Aetna has denied any wrongdoing. The company stated that settling was the practical choice to avoid prolonged litigation costs and uncertainty.
What Is Medicare Advantage Risk Adjustment?
The case centers on a federal health coverage program called Medicare Advantage. Under this system, eligible patients can opt out of traditional Medicare and enroll in health plans managed by private insurance companies. In turn, the government pays these private insurers based on each enrolled patient’s health risk level.
How Risk-Based Payments Work
Patients with serious or complex conditions classify as higher-risk cases. Consequently, insurers receive larger government payments to cover expected treatment costs. This mechanism is called “risk adjustment.” Since payments depend heavily on the diagnosis codes that insurers submit, accurate coding is critical to protecting the integrity of public funds. Even small inaccuracies can cost the government billions over time.
How Aetna Allegedly Inflated Diagnosis Codes
According to investigators, Aetna submitted diagnosis codes that did not match patients’ actual medical records. By overstating the severity of certain conditions, the company allegedly received higher federal reimbursements than it deserved. Furthermore, authorities claim this inaccurate reporting continued from 2018 to 2023 — a span of five years — during which the company consistently submitted flawed data to the government.
Internal Review Failures That Worsened the Allegations
Investigators also discovered that Aetna had identified certain inaccurate diagnosis codes during its own internal reviews. However, the company allegedly failed to fully correct or withdraw that flawed data from its government submissions. As a result, the inaccurate information continued to influence federal payment calculations, compounding the financial impact on public healthcare funds.
Morbid Obesity Codes: The Core Allegation
One of the most specific claims in the case involves the use of morbid obesity diagnosis codes. Morbid obesity is a serious medical condition closely associated with extreme body weight. It carries elevated health risks and places patients in a higher-risk reimbursement category. Investigators alleged that Aetna coded patients with morbid obesity diagnoses even when their Body Mass Index (BMI) data did not support that classification. Since higher-risk categories attract larger government payouts, incorrect obesity coding directly inflated the company’s federal reimbursements.
The Whistleblower Who Exposed the Fraud
The case originated from a whistleblower lawsuit filed by a former risk-adjustment coding auditor based in Arizona. The auditor alleged that the company’s risk adjustment coding process consistently relied on inaccurate medical data. Under U.S. federal law, individuals who expose fraud against the government may receive a share of any funds recovered through their complaint. As part of this settlement, the Arizona auditor is expected to receive around ₹16.6 crore (approximately $2.01 million) as a reward.
Whistleblower cases like this one serve a vital function in government oversight. Since insiders have direct access to internal data and operational practices, they are often uniquely positioned to detect irregularities that external auditors might overlook. In healthcare billing specifically, this kind of internal accountability is difficult to replicate through conventional regulatory checks.
Aetna’s Response and Industry Defense
In its public statement, Aetna maintained that it disagreed with the government’s allegations. Additionally, the company argued that the coding practices in question reflect broader, industry-wide interpretations — not intentional fraud. According to Aetna, settling the case was simply a practical decision to prevent costly and drawn-out legal proceedings. The company has not admitted to any liability as part of the agreement.
Why This Settlement Matters for Public Healthcare
Officials note that private insurance companies collectively receive more than $530 billion annually from the U.S. government to manage Medicare Advantage patients. Given the enormous scale of these payments, even modest inaccuracies in diagnosis coding translate into significant financial losses for public funds. Therefore, the stakes of accurate reporting are exceptionally high across the entire industry.
Moreover, health policy analysts say this case raises critical questions about oversight mechanisms within the Medicare Advantage system. In recent years, program spending has grown substantially, which has prompted authorities to intensify scrutiny of payment accuracy and coding compliance. Legal experts further emphasize that this settlement signals a stronger enforcement trend — U.S. authorities are clearly ramping up efforts to ensure that private insurers accurately report patient data and claim only legitimate reimbursements.
Ultimately, the Aetna settlement stands as an important warning to the healthcare insurance industry. It demonstrates that federal regulators are willing to pursue large-scale fraud allegations aggressively, and that whistleblowers continue to play a decisive role in holding powerful institutions accountable.
